H. Liu-Seifert

发表

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

E. Siemers, R. Mohs, P. Aisen, 2014, The New England journal of medicine.

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.

Haya Ascher-Svanum, Leslie Citrome, J. Volavka, 2009, The Journal of clinical psychiatry.

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

J. Volavka, B. Kinon, H. Liu-Seifert, 2009, Neuropsychiatric disease and treatment.

Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease

E. Siemers, P. Aisen, H. Liu-Seifert, 2015, Alzheimer's & Dementia.

Bone loss associated with hyperprolactinemia in patients with schizophrenia.

B. Kinon, H. Liu-Seifert, V. Stauffer, 2013, Clinical schizophrenia & related psychoses.

Disease Modification in Alzheimer’s Disease: Current Thinking

J. Schumi, H. Liu-Seifert, Xiaopeng Miao, 2019, Therapeutic innovation & regulatory science.

A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee

Jacques P. Brown, Shuyu Zhang, H. Liu-Seifert, 2011, Pain practice : the official journal of World Institute of Pain.

Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain

M. Detke, S. Iyengar, Qi Zhang, 2010, Spine.

A double‐blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain

M. Detke, S. Iyengar, M. Backonja, 2009, European journal of neurology.

Statistical properties of continuous composite scales and implications for drug development

E. Siemers, P. Aisen, S. Hendrix, 2017, Journal of biopharmaceutical statistics.

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

M. Mintun, E. Siemers, R. Dean, 2018, The New England journal of medicine.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

P. Emery, S. Pillai, E. Krishnan, 2019, Annals of the rheumatic diseases.

Randomized, Double-blind 6-Month Comparison of Olanzapine and Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and Poor Functioning

H. Ascher-Svanum, B. Kinon, D. Noordsy, 2006, Journal of clinical psychopharmacology.

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

D. Jeste, B. Kinon, H. Liu-Seifert, 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3

E. Siemers, J. Cummings, R. Mohs, 2018, The journal of prevention of Alzheimer's disease.

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease

E. Siemers, P. Aisen, M. Case, 2017, Alzheimer's & Dementia.

Assessing quality of life in Alzheimer's disease: Implications for clinical trials

E. Siemers, A. Hake, Yun-Fei Chen, 2016, Alzheimer's & dementia.

Function and clinical meaningfulness of treatments for mild Alzheimer's disease

E. Siemers, H. Liu-Seifert, K. Sundell, 2016, Alzheimer's & dementia.

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Robert A. Dean, Eric R. Siemers, E. Siemers, 2016, Alzheimer's & Dementia.

Diagnostic Assessment & Prognosis Function and clinical meaningfulness of treatments for mild Alzheimer's disease

E. Siemers, H. Liu-Seifert, K. Sundell, 2016 .

Featured Article Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

E. Siemers, M. Pontecorvo, R. Dean, 2016 .

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

E. Siemers, P. Aisen, R. Doody, 2015, Alzheimer's & dementia.

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease

Karen L. Price, E. Siemers, J. Cummings, 2015, Journal of Alzheimer's disease : JAD.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

David S. Miller, J. Cummings, P. Aisen, 2015, Alzheimer's Research & Therapy.

Alzheimer’s disease progression by geographical region in a clinical trial setting

David S. Miller, J. Cummings, P. Aisen, 2015, Alzheimer's Research & Therapy.

A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease

E. Siemers, I. Lipkovich, H. Liu-Seifert, 2015, PloS one.

Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.

Karen L. Price, E. Siemers, J. Cummings, 2014, Journal of Alzheimer's disease : JAD.

Title Alzheimer ' s disease progression by geographical region in a clinical trial setting Permalink

David S. Miller, J. Cummings, P. Aisen, 2015 .

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

B. Kinon, H. Liu-Seifert, G. Maguire, 2006, Psychoneuroendocrinology.

A closer look at the baseline-observation-carried-forward (BOCF)

Shuyu Zhang, H. Liu-Seifert, V. Skljarevski, 2010, Patient preference and adherence.

Poster 6: Duloxetine 60 to 120 mg Once Daily Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain

Jacques P. Brown, Shuyu Zhang, H. Liu-Seifert, 2009 .

Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.

B. Kinon, H. Liu-Seifert, S. Kollack-Walker, 2012, Journal of clinical psychopharmacology.

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

B. Kinon, H. Liu-Seifert, D. Adams, 2005, BMC medicine.

Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.

B. Kinon, J. Houston, H. Liu-Seifert, 2007, Journal of clinical psychopharmacology.

Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force

R. Sperling, M. Sabbagh, S. Gauthier, 2019, The Journal of Prevention of Alzheimer's Disease.

Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study

J. Lieberman, J. McEvoy, J. Volavka, 2008, Journal of clinical psychopharmacology.

Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial

R. Bennett, S. Iyengar, H. Liu-Seifert, 2009, PAIN.

Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach

P. Aisen, M. Donohue, M. Rafii, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics

H. Ascher-Svanum, K. Jen, H. Liu-Seifert, 2011, BMC psychiatry.

27. Rapid Onset of Absorption with Olanzapine Orally Disintegrating Tablets

J. Houston, H. Liu-Seifert, J. Witcher, 2004 .

Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease.

E. Siemers, J. Cummings, R. Mohs, 2016, The journal of prevention of Alzheimer's disease.

COGNITIVE IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE

E. Siemers, R. Mohs, P. Aisen, 2014, Alzheimer's & Dementia.

Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.

P. Feldman, H. Liu-Seifert, O. Osuntokun, 2012, Comprehensive psychiatry.

Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia

L. Citrome, B. Kinon, H. Liu-Seifert, 2006, Journal of clinical psychopharmacology.

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia

H. Ascher-Svanum, B. Kinon, D. Faries, 2007, Patient preference and adherence.

Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.

J. Csernansky, J. Peuskens, I. Lipkovich, 2007, Journal of psychiatric research.

Patient perspectives on antipsychotic treatments and their association with clinical outcomes

P. Feldman, H. Liu-Seifert, O. Osuntokun, 2010, Patient preference and adherence.

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

B. Kinon, H. Liu-Seifert, D. Adams, 2005, BMC medicine.

Predictors of premature discontinuation of treatment in multiple disease states

H. Liu-Seifert, V. Skljarevski, E. Nantz, 2009, Patient preference and adherence.

REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING

David S. Miller, J. Cummings, P. Aisen, 2014, Alzheimer's & Dementia.

Disease Modification in Alzheimer’s Disease: Current Thinking

J. Schumi, H. Liu-Seifert, Xiaopeng Miao, 2020, Therapeutic Innovation & Regulatory Science.

Quality of Life – 5 Dimensions ( EQ-5 D ) scale ( proxy version ) , 15 the Quality of Life in Alz

P. Aisen, R. Doody, Ronald G. Thomas, 2014 .